Neoleukin Therapeutics is a biopharmaceutical company, focused on immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. Co. is focused on key cytokine mimetics, which Co. refers to as Neoleukin de novo cytokine mimetics, that can be modified to adjust affinity, thermodynamic stability, resistance to biochemical modification, pharmacokinetic characteristics, potency and targeting to tumor or inflamed tissues. Co.'s NL-201 is designed to mimic the therapeutic activity of the cytokines interleukin-2 and interleukin-15 for the potential treatment of various types of cancer, including renal cell carcinoma, melanoma, and hematological malignancies. The NLTX average annual return since 2014 is shown above.
The Average Annual Return on the NLTX average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether NLTX average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the NLTX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|